Inflammatory Bowel Diseases Clinical Trial
Official title:
The Association of Diabetes Mellitus and Inflammatory Bowel Disease
Diabetes mellitus is a hyperglycemic metabolic disorder due to insulin deficiency or resistance at its receptors, leads to impaired glucose metabolism and multi-organ affection; (optic, peripheral neurological, cardiovascular and renal).
Inflammatory bowel disease; (Crohn's disease and ulcerative colitis), is chronic relapsing
inflammation in the gastrointestinal tract due to complex interactions among genetic,
environmental, gut microbiome, and immunologic factors.
Inflammatory bowel disease treatment inhibits the abnormal inflammatory response to heal
intestinal tissue, relieve the abdominal pain, the diarrhea and the fresh bleeding per
rectum, also decreases the frequency of flare-ups and maintains remission.
Amino-salicylates and antibiotics are step I drugs act on the intestinal lining and on
presented inflammatory masses.
Corticosteroids are step II drugs on failure of step I drugs for adequate control of the
Inflammatory bowel disease and rapid relief of symptoms and inflammation.
The immune modifying agents as azathioprine and 6 mercaptopurine are step III drugs on
failure of the steroids.
Biologic agents are anti Tumor necrotic factor agents (infliximab and adalimumab) and non
anti Tumor necrotic factor agents (vedolizumab, ustekinumab and natalizumab).
Inflammatory bowel disease may have endocrinal and metabolic associations in the form of;
lipid abnormalities and insulin resistance. Also, insulin resistance and hyperglycemia may be
due to steroid use as steroid upgrades (hepatic gluconeogenesis, inhibition of glucose uptake
in adipose tissue, and impairment of insulin action).
There is no epidemiological evidence that Inflammatory bowel disease is a definite risk
factor for diabetes. In this study, the association of diabetes in patients with Inflammatory
bowel disease will be determined.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
Active, not recruiting |
NCT04989907 -
A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Active, not recruiting |
NCT04990258 -
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
|
||
Completed |
NCT06216223 -
Laser Versus Surgery in Anal Diseases in Inflammatory Bowel Patients
|
N/A | |
Enrolling by invitation |
NCT06015789 -
Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
|
||
Recruiting |
NCT06065995 -
StoMakker Mobile Application
|
N/A | |
Recruiting |
NCT03282786 -
Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease
|
N/A | |
Recruiting |
NCT06002074 -
SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT04960826 -
Study of an Environmental Risk Factor in Crohn's Disease
|
||
Recruiting |
NCT05413941 -
Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
Completed |
NCT00721812 -
A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686
|
Phase 1 | |
Recruiting |
NCT05809999 -
IBD Neoplasia Surveillance RCT
|
N/A | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Recruiting |
NCT04991324 -
Cholecalciferol Comedication in IBD - the 5C-study
|
Phase 3 | |
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Not yet recruiting |
NCT05043818 -
A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
|
||
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A |